{"id":153459,"date":"2021-02-26T09:52:00","date_gmt":"2021-02-26T14:52:00","guid":{"rendered":"https:\/\/www.one.org\/us\/?post_type=one_press&p=153459"},"modified":"2021-02-26T09:52:00","modified_gmt":"2021-02-26T14:52:00","slug":"jj-statement","status":"publish","type":"one_press","link":"https:\/\/www.one.org\/us\/press\/jj-statement\/","title":{"rendered":"ONE statement ahead of FDA decision on J&J COVID-19 vaccine"},"content":{"rendered":"

WASHINGTON \u2013 The ONE Campaign released the below statement ahead of the Food and Drug Administration\u2019s decision on the Johnson & Johnson COVID-19 vaccine, which is expected to obtain emergency use approval today.<\/p>\n

In ONE\u2019s updated Vaccine Access Test 2.0 (set for release on March 1) which assesses how well governments and pharmaceutical companies are improving global access to COVID-19 vaccines, Johnson & Johnson is ranked 5th among the 10 companies scored.<\/p>\n

Tom Hart, North America executive director at The ONE Campaign:<\/u><\/strong><\/p>\n

\u201cThe Johnson & Johnson vaccine is welcome news and a positive step towards ending this global pandemic. As the latest COVID-19 variants remind us, the longer this pandemic persists anywhere, the more likely it is that new variants will arise and extend the life of this crisis everywhere.\u00a0It\u2019s in everyone\u2019s interest to get vaccines distributed equitably as quickly as possible.<\/p>\n

\u201cThis news marks another important milestone: the United States has secured enough doses of the five leading vaccines in its pipeline to inoculate the entire US population and have at least 453 million doses<\/a> to spare. It\u2019s urgent that the Biden administration establish a framework and timeline to distribute excess doses to countries who need it while simultaneously vaccinating the US\u2019 domestic population.\u201d<\/p>\n

Background:\u00a0<\/u><\/strong><\/p>\n

In ONE\u2019s soon-to-be released Vaccine Access Test 2.0, Johnson and Johnson scored in the middle of the pack among pharmaceutical companies when it comes to advancing global vaccine access. <\/strong>The company\u2019s actions thus far, such as committing to not-for-profit pricing and committing 100 million vaccine doses to COVAX, have proven a dedication to equitable outcomes, but the company can do more to advance equity. The company can improve its score by engaging in technology transfers and by using its political capital to advocate for equity.<\/p>\n

Global access to vaccines will save lives and make all of us safer.<\/strong>\u00a0Research<\/a>\u00a0shows that in a scenario where a vaccine is not distributed fairly, twice as many people could die as the virus continues to wreak havoc on the world. If a vaccine is distributed exclusively to high-income countries first, the world will only avoid\u00a033% of COVID-19\u00a0<\/a>related deaths. But, if a vaccine is distributed to every country on the globe proportionally to its population rather than prioritizing high-income countries, the world could avoid\u00a061% of COVID-19\u00a0<\/a>related deaths.<\/p>\n

New<\/strong>\u00a0<\/strong>analysis<\/strong><\/a>\u00a0<\/strong>from ONE shows the US has purchased at least 453 million excess COVID-19 vaccine doses that could be used to vaccinate people in the world\u2019s poorest countries.<\/strong>\u00a0<\/strong>According to reports, the Biden administration\u00a0plans<\/a>\u00a0to develop a framework to donate excess vaccine doses, but to date, no formal plan has been released. Experts warn that wealthy countries hoarding scarce vaccine doses could extend the lifespan of this pandemic. Leaders, including French President Emmanuel Macron, have\u00a0called<\/a>\u00a0on countries to allocate 4-5% of their vaccine doses to low-income countries.<\/p>\n

Ensuring global access to a vaccine will not only end the pandemic sooner, but will boost the global economy.<\/strong>\u00a0<\/strong>The economic cost of not distributing a vaccine everywhere would be enormous. A\u00a0<\/strong>recent\u00a0study<\/a>\u00a0found the global economy stands to lose as much as $9.2 trillion if governments fail to ensure developing economy access to COVID-19 vaccine.<\/p>\n

The American people support global access to a vaccine around the world<\/strong>. An October 2020 poll of registered voters in the US found that 83 percent of Americans believe that healthcare workers, the elderly and at-risk groups\u00a0anywhere in the world<\/u><\/em>\u00a0should be the first to get a COVID-19 vaccine, before healthy people in their own country.<\/p>\n

<\/div>","protected":false},"excerpt":{"rendered":"

WASHINGTON \u2013 The ONE Campaign released the below statement ahead of the Food and Drug Administration\u2019s decision on the Johnson & Johnson COVID-19 vaccine, which is expected to obtain emergency use approval today. In ONE\u2019s updated Vaccine Access Test 2.0 (set for release on March 1) which assesses how well governments and pharmaceutical companies are […]<\/p>\n","protected":false},"author":1,"featured_media":0,"template":"","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"contributor":[],"class_list":["post-153459","one_press","type-one_press","status-publish","hentry"],"acf":[],"yoast_head":"\nONE statement ahead of FDA decision on J&J COVID-19 vaccine - ONE.org US<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.one.org\/us\/press\/jj-statement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ONE statement ahead of FDA decision on J&J COVID-19 vaccine\" \/>\n<meta property=\"og:description\" content=\"WASHINGTON \u2013 The ONE Campaign released the below statement ahead of the Food and Drug Administration\u2019s decision on the Johnson & Johnson COVID-19 vaccine, which is expected to obtain emergency use approval today. In ONE\u2019s updated Vaccine Access Test 2.0 (set for release on March 1) which assesses how well governments and pharmaceutical companies are […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.one.org\/us\/press\/jj-statement\/\" \/>\n<meta property=\"og:site_name\" content=\"ONE.org US\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ONE\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.one.org\/us\/wp-content\/uploads\/sites\/2\/2023\/09\/GA_share_1200x628-768x402-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"768\" \/>\n\t<meta property=\"og:image:height\" content=\"402\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ONEinAmerica\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.one.org\/us\/press\/jj-statement\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.one.org\/us\/press\/jj-statement\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/www.one.org\/us\/#\/schema\/person\/236ef43a079c36667c3f1de2da8e0838\"},\"headline\":\"ONE statement ahead of FDA decision on J&J COVID-19 vaccine\",\"datePublished\":\"2021-02-26T14:52:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.one.org\/us\/press\/jj-statement\/\"},\"wordCount\":595,\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.one.org\/us\/press\/jj-statement\/\",\"url\":\"https:\/\/www.one.org\/us\/press\/jj-statement\/\",\"name\":\"ONE statement ahead of FDA decision on J&J COVID-19 vaccine - ONE.org US\",\"isPartOf\":{\"@id\":\"https:\/\/www.one.org\/us\/#website\"},\"datePublished\":\"2021-02-26T14:52:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.one.org\/us\/press\/jj-statement\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.one.org\/us\/press\/jj-statement\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.one.org\/us\/press\/jj-statement\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.one.org\/us\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ONE statement ahead of FDA decision on J&J COVID-19 vaccine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.one.org\/us\/#website\",\"url\":\"https:\/\/www.one.org\/us\/\",\"name\":\"ONE.org\",\"description\":\"Driving economic opportunities and healthy lives in Africa\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.one.org\/us\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.one.org\/us\/#\/schema\/person\/236ef43a079c36667c3f1de2da8e0838\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.one.org\/us\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2b4204681b789d34ede86a735f8b6378df901f7f7ab7a9ca89af4670b2bb13b8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2b4204681b789d34ede86a735f8b6378df901f7f7ab7a9ca89af4670b2bb13b8?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"http:\/\/www.one.org\"],\"url\":\"https:\/\/www.one.org\/us\/stories\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ONE statement ahead of FDA decision on J&J COVID-19 vaccine - ONE.org US","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.one.org\/us\/press\/jj-statement\/","og_locale":"en_US","og_type":"article","og_title":"ONE statement ahead of FDA decision on J&J COVID-19 vaccine","og_description":"WASHINGTON \u2013 The ONE Campaign released the below statement ahead of the Food and Drug Administration\u2019s decision on the Johnson & Johnson COVID-19 vaccine, which is expected to obtain emergency use approval today. In ONE\u2019s updated Vaccine Access Test 2.0 (set for release on March 1) which assesses how well governments and pharmaceutical companies are […]","og_url":"https:\/\/www.one.org\/us\/press\/jj-statement\/","og_site_name":"ONE.org US","article_publisher":"https:\/\/www.facebook.com\/ONE","og_image":[{"width":768,"height":402,"url":"https:\/\/www.one.org\/us\/wp-content\/uploads\/sites\/2\/2023\/09\/GA_share_1200x628-768x402-1.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@ONEinAmerica","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.one.org\/us\/press\/jj-statement\/#article","isPartOf":{"@id":"https:\/\/www.one.org\/us\/press\/jj-statement\/"},"author":{"name":"admin","@id":"https:\/\/www.one.org\/us\/#\/schema\/person\/236ef43a079c36667c3f1de2da8e0838"},"headline":"ONE statement ahead of FDA decision on J&J COVID-19 vaccine","datePublished":"2021-02-26T14:52:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.one.org\/us\/press\/jj-statement\/"},"wordCount":595,"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.one.org\/us\/press\/jj-statement\/","url":"https:\/\/www.one.org\/us\/press\/jj-statement\/","name":"ONE statement ahead of FDA decision on J&J COVID-19 vaccine - ONE.org US","isPartOf":{"@id":"https:\/\/www.one.org\/us\/#website"},"datePublished":"2021-02-26T14:52:00+00:00","breadcrumb":{"@id":"https:\/\/www.one.org\/us\/press\/jj-statement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.one.org\/us\/press\/jj-statement\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.one.org\/us\/press\/jj-statement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.one.org\/us\/"},{"@type":"ListItem","position":2,"name":"ONE statement ahead of FDA decision on J&J COVID-19 vaccine"}]},{"@type":"WebSite","@id":"https:\/\/www.one.org\/us\/#website","url":"https:\/\/www.one.org\/us\/","name":"ONE.org","description":"Driving economic opportunities and healthy lives in Africa","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.one.org\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.one.org\/us\/#\/schema\/person\/236ef43a079c36667c3f1de2da8e0838","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.one.org\/us\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/2b4204681b789d34ede86a735f8b6378df901f7f7ab7a9ca89af4670b2bb13b8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2b4204681b789d34ede86a735f8b6378df901f7f7ab7a9ca89af4670b2bb13b8?s=96&d=mm&r=g","caption":"admin"},"sameAs":["http:\/\/www.one.org"],"url":"https:\/\/www.one.org\/us\/stories\/author\/admin\/"}]}},"distributor_meta":false,"distributor_terms":false,"distributor_media":false,"distributor_original_site_name":"ONE.org US","distributor_original_site_url":"https:\/\/www.one.org\/us","push-errors":false,"_links":{"self":[{"href":"https:\/\/www.one.org\/us\/wp-json\/wp\/v2\/one_press\/153459","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.one.org\/us\/wp-json\/wp\/v2\/one_press"}],"about":[{"href":"https:\/\/www.one.org\/us\/wp-json\/wp\/v2\/types\/one_press"}],"author":[{"embeddable":true,"href":"https:\/\/www.one.org\/us\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":0,"href":"https:\/\/www.one.org\/us\/wp-json\/wp\/v2\/one_press\/153459\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.one.org\/us\/wp-json\/wp\/v2\/media?parent=153459"}],"wp:term":[{"taxonomy":"contributor","embeddable":true,"href":"https:\/\/www.one.org\/us\/wp-json\/wp\/v2\/contributor?post=153459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}